Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

PURPOSE: We aimed to explore whether the prognosis of patients treated with capecitabine and oxaliplatin (XELOX) or S-1 and oxaliplatin (SOX) regimens who received fewer cycles of chemotherapy after D2 radical resection for gastric cancer (GC) would be non-inferior to that of patients who received t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yuanyuan, Zhang, Zicheng, Meng, Qianhao, Wang, Ke, Li, Qingwei, Ma, Yue, Yao, Yuanfei, Sun, Jie, Wang, Guangyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Gastric Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091457/
https://www.ncbi.nlm.nih.gov/pubmed/35534448
http://dx.doi.org/10.5230/jgc.2022.22.e11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091457/
https://www.ncbi.nlm.nih.gov/pubmed/35534448
http://dx.doi.org/10.5230/jgc.2022.22.e11

Ejemplares similares